Waldenstrom Macroglobulinemia Archives - Page 3 of 5

Hematologic Cancers

Waldenström Macroglobulinemia Symptoms May be Gastro-Related

By

Christina Bennett, MS

November 12, 2019

Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.

More Edema With Bacteriuria in Hereditary Angioedema With Deficiency

Hematologic Cancers

Novel Therapies on the Horizon for Waldenström Macroglobulinemia

By

Christina Bennett, MS

November 8, 2019

New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.

Women who survive breast cancer may have a higher-than-average risk of developing thyroid cancer in

Hematologic Cancers

Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia

By

Susan Moench, PhD, PA-C

October 15, 2019

In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.

Telotristat represents a new treatment option that may decrease diarrhea incidence with a relatively

Hematologic Cancers

CXCR4^S338X Clonality Predicts Ibrutinib Outcomes in Waldenström Macroglobulinemia

By

Christina Bennett, MS

October 11, 2019

WM patients with high CXCR4S338X clonality had worse outcomes after ibrutinib therapy compared with patients who had low CXCR4S338X clonality.

A review published in Blood highlights new approaches that are being investigated to treat PCNSL bas

Hematologic Cancers

Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement

By

Susan Moench, PhD, PA-C

September 17, 2019

According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic im

Hematologic Cancers

Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia

By

Christina Bennett, MS

September 17, 2019

A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immu

Hematologic Cancers

Single-Agent Ibrutinib Versus Rituximab-Based Chemoimmunotherapy in Waldenström Macroglobulinemia

By

Susan Moench, PhD, PA-C

August 13, 2019

No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.

Researchers found that doubling in KIM-1 plasma concentrations were associated with an increased ris

Hematologic Cancers

Rituximab Maintenance Therapy in Waldenström Macroglobulinemia: Yay or Nay?

By

Susan Moench, PhD, PA-C

August 8, 2019

A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.